Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
PLoS One ; 13(7): e0200342, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30044800

RESUMEN

OBJECTIVE: We sought to define the intrinsic stem cell capacity in pediatric heart lesions, and the effects of diagnosis and of age, in order to inform evidence-based use of potential autologous stem cell sources for regenerative medicine therapy. METHODS: Ventricular explants derived from patients with hypoplastic left heart syndrome (HLHS), tetralogy of Fallot (TF), dilated cardiomyopathy (DCM) and ventricular septal defect (VSD) were analyzed following standard in vitro culture conditions, which yielded cardiospheres (C-spheres), indicative of endogenous stem cell capacity. C-sphere counts generated per 5 mm3 tissue explant and the presence of cardiac progenitor cells were correlated to patient age, diagnosis and echocardiographic function. RESULTS: Cardiac explants from patients less than one year of age with TF and DCM robustly generated c-kit- and/or vimentin-positive cardiac mesenchymal cells (CMCs), populating spontaneously forming C-spheres. Beyond one year of age, there was a marked reduction or absence of cardiac explant-derivable cardiac stem cell content in patients with TF, VSD and DCM. Stem cell content in HLHS and DCM strongly correlated to the echocardiographic function in the corresponding ventricular chamber, with better echocardiographic function correlating to a more robust regenerative cellular content. CONCLUSIONS: We conclude that autologous cardiomyogenic potential in pediatric heart lesions is robust during the first year of life and uniformly declines thereafter. Depletion of stem cell content occurs at an earlier age in HLHS with the onset of ventricular failure in a chamber-specific pattern that correlates directly to ventricular dysfunction. These data suggest that regenerative therapies using autologous cellular sources should be implemented in the neonatal period before the potentially rapid onset of single ventricle failure in HLHS or the evolution of biventricular failure in DCM.


Asunto(s)
Cardiomiopatía Dilatada/fisiopatología , Defectos del Tabique Interventricular/fisiopatología , Ventrículos Cardíacos/fisiopatología , Síndrome del Corazón Izquierdo Hipoplásico/fisiopatología , Regeneración , Tetralogía de Fallot/fisiopatología , Adolescente , Envejecimiento/patología , Envejecimiento/fisiología , Cardiomiopatía Dilatada/diagnóstico por imagen , Cardiomiopatía Dilatada/patología , Cardiomiopatía Dilatada/cirugía , Células Cultivadas , Niño , Preescolar , Electrocardiografía , Defectos del Tabique Interventricular/diagnóstico por imagen , Defectos del Tabique Interventricular/patología , Defectos del Tabique Interventricular/cirugía , Ventrículos Cardíacos/diagnóstico por imagen , Ventrículos Cardíacos/patología , Ventrículos Cardíacos/cirugía , Humanos , Síndrome del Corazón Izquierdo Hipoplásico/diagnóstico por imagen , Síndrome del Corazón Izquierdo Hipoplásico/patología , Síndrome del Corazón Izquierdo Hipoplásico/cirugía , Lactante , Recién Nacido , Células Madre Mesenquimatosas/patología , Células Madre Mesenquimatosas/fisiología , Miocitos Cardíacos/patología , Miocitos Cardíacos/fisiología , Regeneración/fisiología , Tetralogía de Fallot/diagnóstico por imagen , Tetralogía de Fallot/patología , Tetralogía de Fallot/cirugía , Técnicas de Cultivo de Tejidos
3.
Data Brief ; 7: 1148-50, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27408918

RESUMEN

Using hearts from mice overexpressing integrin linked kinase (ILK) behind the cardiac specific promoter αMHC, we have performed immunoprecipitation and mass spectrometry to identify novel ILK protein:protein interactions that regulate cardiomyocyte activity and calcium flux. Integrin linked kinase complexes were captured from mouse heart lysates using a commercial antibody, with subsequent liquid chromatography tandem mass spectral analysis. Interacting partners were identified using the MASCOT server, and important interactions verified using reverse immunoprecipitation and mass spectrometry. All ILK interacting proteins were identified in a non-biased manner, and are stored in the ProteomeXchange Consortium via the PRIDE partner repository (reference ID PRIDE: PXD001053). The functional role of identified ILK interactions in cardiomyocyte function and arrhythmia were subsequently confirmed in human iPSC-cardiomyocytes.

4.
Nat Commun ; 5: 4533, 2014 Sep 11.
Artículo en Inglés | MEDLINE | ID: mdl-25208486

RESUMEN

Human dilated cardiomyopathy (DCM) manifests as a profound reduction in biventricular cardiac function that typically progresses to death or cardiac transplantation. There is no effective mechanism-based therapy currently available for DCM, in part because the transduction of mechanical load into dynamic changes in cardiac contractility (termed mechanotransduction) remains an incompletely understood process during both normal cardiac function and in disease states. Here we show that the mechanoreceptor protein integrin-linked kinase (ILK) mediates cardiomyocyte force transduction through regulation of the key calcium regulatory protein sarcoplasmic/endoplasmic reticulum Ca(2+)ATPase isoform 2a (SERCA-2a) and phosphorylation of phospholamban (PLN) in the human heart. A non-oncogenic ILK mutation with a synthetic point mutation in the pleckstrin homology-like domain (ILK(R211A)) is shown to enhance global cardiac function through SERCA-2a/PLN. Thus, ILK serves to link mechanoreception to the dynamic modulation of cardiac contractility through a previously undiscovered interaction with the functional SERCA-2a/PLN module that can be exploited to rescue impaired mechanotransduction in DCM.


Asunto(s)
Proteínas de Unión al Calcio/metabolismo , Mecanotransducción Celular/genética , Contracción Miocárdica/genética , Miocitos Cardíacos/metabolismo , Proteínas Serina-Treonina Quinasas/genética , ATPasas Transportadoras de Calcio del Retículo Sarcoplásmico/metabolismo , Animales , Humanos , Células Madre Pluripotentes Inducidas , Mecanotransducción Celular/fisiología , Ratones , Ratones Noqueados , Contracción Miocárdica/fisiología , Fosforilación , Proteínas Serina-Treonina Quinasas/metabolismo , Retículo Sarcoplasmático/metabolismo
5.
J Thorac Cardiovasc Surg ; 148(1): 245-53, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24084286

RESUMEN

BACKGROUND: Surgical and catheter-based interventions on pulmonary veins are associated with pulmonary vein stenosis (PVS), which can progress diffusely through the "upstream" pulmonary veins. The mechanism has been rarely studied. We used a porcine model of PVS to assess disease progression with emphasis on the potential role of endothelial-mesenchymal transition (EndMT). METHODS: Neonatal piglets underwent bilateral pulmonary vein banding (banded, n = 6) or sham operations (sham, n = 6). Additional piglets underwent identical banding and stent implantation in a single-banded pulmonary vein 3 weeks postbanding (stented, n = 6). At 7 weeks postbanding, hemodynamics and upstream PV pathology were assessed. RESULTS: Banded piglets developed pulmonary hypertension. The upstream pulmonary veins exhibited intimal thickening associated with features of EndMT, including increased transforming growth factor (TGF)-ß1 and Smad expression, loss of endothelial and gain of mesenchymal marker expression, and coexpression of endothelial and mesenchymal markers in banded pulmonary vein intimal cells. These immunopathologic changes and a prominent myofibroblast phenotype in the remodeled pulmonary veins were consistently identified in specimens from patients with PVS, in vitro TGF-ß1-stimulated cells isolated from piglet and human pulmonary veins, and human umbilical vein endothelial cells. After stent implantation, decompression of a pulmonary vein was associated with reappearance of endothelial marker expression, suggesting the potential for plasticity in the observed pathologic changes, followed by rapid in-stent restenosis. CONCLUSIONS: Neonatal pulmonary vein banding in piglets recapitulates critical aspects of clinical PVS and highlights a pathologic profile consistent with EndMT, supporting the rationale for evaluating therapeutic strategies designed to exploit reversibility of upstream pulmonary vein pathology.


Asunto(s)
Venas Pulmonares/fisiopatología , Enfermedad Veno-Oclusiva Pulmonar/fisiopatología , Animales , Animales Recién Nacidos , Biomarcadores/metabolismo , Células Cultivadas , Constricción Patológica , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Transición Epitelial-Mesenquimal , Hemodinámica , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Células Endoteliales de la Vena Umbilical Humana/patología , Hiperplasia , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/metabolismo , Hipertensión Pulmonar/fisiopatología , Miofibroblastos/metabolismo , Miofibroblastos/patología , Neointima , Fenotipo , Venas Pulmonares/metabolismo , Venas Pulmonares/patología , Enfermedad Veno-Oclusiva Pulmonar/complicaciones , Enfermedad Veno-Oclusiva Pulmonar/metabolismo , Enfermedad Veno-Oclusiva Pulmonar/patología , Recurrencia , Proteínas Smad/metabolismo , Porcinos , Factores de Tiempo , Factor de Crecimiento Transformador beta1/metabolismo
6.
PLoS One ; 8(11): e77331, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24260102

RESUMEN

RATIONALE: Integrin-linked kinase (ILK) has been proposed as a novel molecular target that has translational potential in diverse cardiac diseases, since its upregulation promotes a broadly cardioprotective phenotype. However, ILK has been implicated as both a cardioprotective and oncogenic target, which imposes therapeutic constraints that are generally relevant to the translational potential of many kinases. OBJECTIVE: To study the cardioprotective properties of the activation-resistant, non-oncogenic, mutation of ILK (ILK(R211A)) against experimental MI in vivo and Doxorubicin induced apoptosis in vitro and it's relationships to stress induced heat shock proteins. METHODS/RESULTS: The transgenic mouse heart over-expressing a point mutation in the ILK pleckstrin homology (PH) domain (Tg(R211A)) exhibits a highly cardioprotective phenotype based on LAD-ligation-induced MI reduction in vivo, and on protection against doxorubicin (DOX)-induced cardiomyocyte apoptosis when overexpressed in human induced pluripotent stem cell (iPS)-derived cardiomyocytes in vitro. Intriguingly, the degree of cardioprotection seen with the ILK(R211A) mutation exceeded that with the ILK(S343D) mutation. Microarray and immunoprecipitation analyses revealed upregulation of expression levels and specific binding of ILK(WT), ILK(S343D) and ILK(R211A) to both constitutively active heat-shock protein 70 (Hsc70) and inducible Hsp70 in response to MI, and to acute ILK overexpression in iPSC-cardiomyocytes. ILK-mediated cardioprotection was shown to depend upon Hsp70 ATPase activity. CONCLUSIONS: These findings indicate that wild type ILK and the non-oncogenic ILK(R211A) mutation comprise a cardioprotective module with Hsp/c70. These results advance a novel target discovery theme in which kinase mutations can be safely engineered to enhance cardioprotective effects.


Asunto(s)
Proteínas del Choque Térmico HSC70/metabolismo , Mutación Missense , Infarto del Miocardio/metabolismo , Miocitos Cardíacos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Sustitución de Aminoácidos , Animales , Antibióticos Antineoplásicos/efectos adversos , Antibióticos Antineoplásicos/farmacología , Doxorrubicina/efectos adversos , Doxorrubicina/farmacología , Proteínas del Choque Térmico HSC70/genética , Humanos , Ratones , Ratones Transgénicos , Infarto del Miocardio/genética , Infarto del Miocardio/patología , Miocardio/metabolismo , Miocardio/patología , Miocitos Cardíacos/patología , Proteínas Serina-Treonina Quinasas/genética , Conejos
7.
PLoS One ; 7(5): e37802, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22666394

RESUMEN

BACKGROUND: Integrin-linked kinase (ILK) is a widely conserved serine/threonine kinase that regulates diverse signal transduction pathways implicated in cardiac hypertrophy and contractility. In this study we explored whether experimental overexpression of ILK would up-regulate morphogenesis in the human fetal heart. METHODOLOGY/PRINCIPAL FINDINGS: Primary cultures of human fetal myocardial cells (19-22 weeks gestation) yielded scattered aggregates of cardioblasts positive for the early cardiac lineage marker nk × 2.5 and containing nascent sarcomeres. Cardiac cells in colonies uniformly expressed the gap junction protein connexin 43 (C × 43) and displayed a spectrum of differentiation with only a subset of cells exhibiting the late cardiomyogenic marker troponin T (cTnT) and evidence of electrical excitability. Adenovirus-mediated overexpression of ILK potently increased the number of new aggregates of primitive cardioblasts (p<0.001). The number of cardioblast colonies was significantly decreased (p<0.05) when ILK expression was knocked down with ILK targeted siRNA. Interestingly, overexpression of the activation resistant ILK mutant (ILK(R211A)) resulted in much greater increase in the number of new cell aggregates as compared to overexpression of wild-type ILK (ILK(WT)). The cardiomyogenic effects of ILK(R211A) and ILK(WT) were accompanied by concurrent activation of ß-catenin (p<0.001) and increase expression of progenitor cell marker islet-1, which was also observed in lysates of transgenic mice with cardiac-specific over-expression of ILK(R211A) and ILK(WT). Finally, endogenous ILK expression was shown to increase in concert with those of cardiomyogenic markers during directed cardiomyogenic differentiation in human embryonic stem cells (hESCs). CONCLUSIONS/SIGNIFICANCE: In the human fetal heart ILK activation is instructive to the specification of mesodermal precursor cells towards a cardiomyogenic lineage. Induction of cardiomyogenesis by ILK overexpression bypasses the requirement of proximal PI3K activation for transduction of growth factor- and ß1-integrin-mediated differentiation signals. Altogether, our data indicate that ILK represents a novel regulatory checkpoint during human cardiomyogenesis.


Asunto(s)
Miocardio/citología , Miocardio/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Miosinas Cardíacas , Agregación Celular , Fenómenos Electrofisiológicos , Células Madre Embrionarias/citología , Células Madre Embrionarias/metabolismo , Activación Enzimática , Femenino , Feto/citología , Regulación de la Expresión Génica , Humanos , Proteínas con Homeodominio LIM/genética , Mioblastos Cardíacos/citología , Mioblastos Cardíacos/metabolismo , Miocitos Cardíacos/citología , Miocitos Cardíacos/metabolismo , Cadenas Pesadas de Miosina/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Embarazo , Transporte de Proteínas , Sarcómeros/metabolismo , Factores de Transcripción/genética
8.
Biochem J ; 410(3): 503-11, 2008 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-17967162

RESUMEN

Glypicans are heparan sulfate proteoglycans that are attached to the cell surface by a GPI (glycosylphosphatidylinositol)anchor. Glypicans regulate the activity of Wnts, Hedgehogs,bone morphogenetic proteins and fibroblast growth factors. In the particular case of Wnts, it has been proposed that GPI-anchored glypicans stimulate Wnt signalling by facilitating and/or stabilizing the interaction between Wnts and their cell surface receptors. On the other hand, when glypicans are secreted to the extracellular environment, they can act as competitive inhibitors of Wnt. Genetic screens in Drosophila have recently identified a novel inhibitor of Wnt signalling named Notum. The Wnt inhibiting activity of Notum was associated with its ability to release Dlp [Dally (Division abnormally delayed)-like protein; a Drosophila glypican] from the cell surface by cleaving the GPI anchor. Because these studies showed that the other Drosophila glypican Dally was not released from the cell surface by Notum,it remains unclear whether this enzyme is able to cleave glypicans from mammalian cells. Furthermore, it is also not known whether Notum cleaves GPI-anchored proteins that are not members of the glypican family. Here, we show that mammalian Notum can cleave several mammalian glypicans. Moreover, we demonstrate that Notum is able to release GPI-anchored proteins other than glypicans. Another important finding of the present study is that,unlike GPI-phospholipase D, the other mammalian enzyme that cleaves GPI-anchored proteins, Notum is active in the extracellular environment. Finally, by using a cellular system in which GPC3 (glypican-3) stimulates Wnt signalling, we show that Notum can act as a negative regulator of this growth factor.


Asunto(s)
Membrana Celular/metabolismo , Proteínas de Drosophila/genética , Proteínas Ligadas a GPI/metabolismo , Glicosilfosfatidilinositoles/metabolismo , Proteínas Wnt/metabolismo , Animales , Drosophila/genética , Proteínas de Drosophila/metabolismo , Espacio Extracelular/metabolismo , Glipicanos/metabolismo , Células HEK293 , Humanos , Ratones , Conejos , Transfección
9.
J Gastroenterol Hepatol ; 22(12): 2189-94, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18031379

RESUMEN

BACKGROUND AND AIM: It has been shown in previous studies that hypothyroidism prevents the development of liver fibrosis in bile duct ligated rats and in rats chronically treated with thioacetamide (TAA). In recent years, regression of liver fibrosis (occurring spontaneously or during treatment) has been demonstrated in rodent models such as bile duct ligation and CCl(4) administration. Therefore, in the present study, the potential therapeutic effect of hypothyroidism on liver fibrosis was investigated. METHODS: Liver fibrosis was induced in rats by administration of TAA (200 mg/kg, i.p., twice weekly) for 12 weeks. Hypothyroidism was then induced by either methimazole (0.04%) or propylthiouracil (0.05%) administered in drinking water for 8 weeks. Control euthyroid rats received normal drinking water. Hypothyroidism was confirmed by a significant elevation of serum thyroid-stimulating hormone levels. RESULTS: Eight weeks after the cessation of TAA administration, spleen weight, histological score of liver fibrosis, and hepatic hydroxyproline content were significantly lower in both groups of hypothyroid rats as compared to euthyroid controls (P < 0.001). In vitro studies using the rat hepatic stellate cell line HSC-T6 using northern blot analysis and zymography, respectively, showed that high concentrations of triiodotyronine (T(3)) enhanced transforming growth factor (TGF)-beta-induced collagen I gene expression, and reduced metalloproteinase (MMP)-2 secretion, implying that reducing the levels of T(3) may contribute to resolution of fibrosis. Additionally, low T(3) concentration inhibited HSC-T6 proliferation. CONCLUSION: Pharmacologically induced hypothyroidism accelerates the resolution of liver fibrosis in rats. This beneficial effect may in part be due to prevention of T(3)-induced stimulation of collagen synthesis and reduction of MMP-2 secretion.


Asunto(s)
Hipotiroidismo/complicaciones , Cirrosis Hepática/complicaciones , Animales , Línea Celular , Proliferación Celular/efectos de los fármacos , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Hepatocitos/citología , Hepatocitos/efectos de los fármacos , Hepatocitos/enzimología , Hepatocitos/metabolismo , Hipotiroidismo/inducido químicamente , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Ratas , Ratas Wistar , Factor de Crecimiento Transformador beta/farmacología , Triyodotironina/farmacología
10.
Scand J Gastroenterol ; 40(10): 1226-34, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16165703

RESUMEN

OBJECTIVE: Nicotinamide has been shown to inhibit proliferation and induce apoptosis in a variety of cells. Moreover, nicotinamide treatment attenuates collagen accumulation and fibrogenesis in the bleomycin model of lung fibrosis. We hypothesized that nicotinamide may be useful as an antifibrotic agent in liver fibrosis and we investigated the in vitro effect of nicotinamide on hepatic stellate cells proliferation, apoptosis and collagen I expression. MATERIAL AND METHODS: Transforming growth factor beta1 (TGF-beta1) was used for activation of the rat HSC-T6 cell line. Apoptosis was determined by fluorescence activated cell sorter (FACS) analysis after propidium iodide staining and by immunohistochemistry showing presence of the active form of caspase 3. Expression of activation marker alpha-smooth muscle actin (alpha-SMA), apoptotic and cell cycle markers cyclin D1, P53 and caspase 3 was determined by Western blotting. Collagen I expression was assessed by Northern blotting. RESULTS: Nicotinamide inhibits hepatic stellate cell proliferation and induces apoptosis with caspase-3 activation. There is no effect of nicotinamide on the levels of cell cycle stimulator cyclin D1. Expression of p53 is induced in the presence of nicotinamide. Nicotinamide reduces activation marker alpha-SMA and decreases both basal and TGFbetaepsilon-induced collagen I expression. Moreover, in TGFbeta-activated cells, nicotinamide reduces expression of pro-inflammatory and pro-fibrotic cytokines TGFbeta2, IL-1beta, TNFalpha and macrophage chemotactic protein-1. CONCLUSIONS: The in vitro effect of nicotinamide on activation and proliferation of hepatic stellate cells suggests that nicotinamide may have a potential beneficial role in attenuation of liver fibrogenesis.


Asunto(s)
Apoptosis/efectos de los fármacos , Colágeno Tipo I/efectos de los fármacos , Citocinas/efectos de los fármacos , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Niacinamida/farmacología , Complejo Vitamínico B/farmacología , Actinas/efectos de los fármacos , Actinas/metabolismo , Animales , Northern Blotting , Western Blotting , Caspasa 3 , Caspasas/efectos de los fármacos , Caspasas/metabolismo , Ciclo Celular/efectos de los fármacos , Línea Celular , Proliferación Celular/efectos de los fármacos , Colágeno Tipo I/biosíntesis , Ciclina D1/efectos de los fármacos , Ciclina D1/metabolismo , Citocinas/biosíntesis , Activación Enzimática/efectos de los fármacos , Citometría de Flujo , Gliceraldehído-3-Fosfato Deshidrogenasas/efectos de los fármacos , Gliceraldehído-3-Fosfato Deshidrogenasas/metabolismo , Hepatocitos/patología , Inmunohistoquímica , Mediadores de Inflamación/metabolismo , Cirrosis Hepática/metabolismo , Ratas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Inhibidores Tisulares de Metaloproteinasas/efectos de los fármacos , Inhibidores Tisulares de Metaloproteinasas/metabolismo , Proteína p53 Supresora de Tumor/efectos de los fármacos , Proteína p53 Supresora de Tumor/metabolismo
11.
Liver Transpl ; 11(8): 929-33, 2005 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16035058

RESUMEN

We recently developed a novel rat model for liver repopulation, heterografting of microliver slices, aimed at overcoming the limitations inherent in both whole liver and hepatocyte transplantations. The aim of the present study was to evaluate the potential of whole fetal liver transplantations to survive and differentiate within the adult liver, using the adult liver slice transplantation model. Embryonic day 14 whole fetal livers from dipeptidyl peptidase IV+/+ wild-type Fischer 344 rats were transplanted into the livers of dipeptidyl peptidase IV-/- mutant rats. Adult hepatic markers, dipeptidyl peptidase IV, albumin, glycogen, and proliferation cell nuclear antigen- proliferation cell nuclear antigen (PCNA) were assessed in the transplanted liver tissue by immunohistochemistry. Two groups of 9 rats each were transplanted with 3 fetal livers per recipient. Two months later the rats were sacrificed and the markers were detected in the transplanted tissues. In conclusion, the results of this study raise the possibility that fetal liver transplantation could serve as a model for genetic metabolic liver diseases.


Asunto(s)
Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Trasplante de Tejido Fetal , Trasplante de Hígado , Albúminas/metabolismo , Animales , Animales Modificados Genéticamente , Biomarcadores/metabolismo , Dipeptidil Peptidasa 4/genética , Dipeptidil Peptidasa 4/metabolismo , Femenino , Eliminación de Gen , Glucógeno/metabolismo , Supervivencia de Injerto , Inmunohistoquímica , Hígado/embriología , Hígado/metabolismo , Masculino , Antígeno Nuclear de Célula en Proliferación/metabolismo , Ratas , Ratas Endogámicas F344 , Trasplante Heterólogo
12.
J Cell Physiol ; 200(2): 245-52, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15174094

RESUMEN

A novel recombinant molecule, termed IL-6c and consisting of a chimera of interleukin 6 (IL-6) and its soluble receptor is extremely potent in stimulating proliferation of hematopoietic progenitors. We investigated the effect of the IL-6c on the proliferation and differentiation of E14 fetal hepatocytes. IL-6c, in a dose-dependent manner, stimulated proliferation of E14 fetal rat hepatocytes. Adult hepatocyte mitogens together with IL-6c showed no further effect on proliferation. Hematopoietic stem cells mitogens SCF and flt3 ligand (FL) were also mitogenic for fetal hepatocytes, but did not further enhance the effect of IL-6c on cell proliferation. IL-6c decreased expression of fetal markers alpha-fetoprotein (AFP) and gamma-glutamyltranspeptidase, and induced expression of adult enzyme glucose-6-phosphatase (Gluc-6-P) in E14 hepatocytes. On the other hand, IL-6c strongly reduced, in a dose-dependant manner, expression of albumin and tyrosine aminotransferase (TAT). However, when the cells were grown for 3 days with IL-6c, and IL-6c was removed for the next 5 days, expression of albumin and TAT returned to levels found in control cultures. In conclusion, IL-6c stimulated proliferation and affected gene expression in fetal hepatocytes in culture.


Asunto(s)
Diferenciación Celular/fisiología , División Celular/fisiología , Células Madre Hematopoyéticas/metabolismo , Hepatocitos/metabolismo , Mitógenos/farmacología , Receptores de Interleucina-6/metabolismo , Adenosina Trifosfatasas/metabolismo , Animales , Western Blotting , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Células Cultivadas , Dipeptidil Peptidasa 4/metabolismo , Sangre Fetal/citología , Feto/citología , Feto/embriología , Feto/metabolismo , Citometría de Flujo , Glucosa-6-Fosfatasa/metabolismo , Glucógeno/biosíntesis , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/efectos de los fármacos , Hepatocitos/citología , Hepatocitos/efectos de los fármacos , Hepatocitos/enzimología , Inmunohistoquímica , Ratas , Ratas Endogámicas F344 , Receptores de Interleucina-6/genética , Proteínas Recombinantes/metabolismo , Solubilidad , gamma-Glutamiltransferasa/metabolismo
13.
Exp Cell Res ; 288(2): 354-62, 2003 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-12915126

RESUMEN

Endogenous nitric oxide (NO) has recently been shown to affect cell cycle progression in the neural tube (NT) of the chick embryo. High NO levels trigger entry into S phase basally, while low NO levels facilitate mitosis apically. Here, we further explore the involvement of NO in determining cell numbers in the chick NT. In addition to the effect of short-term (6 h) NOS inhibition, we have observed a concomitant decrease in programmed cell death (PCD). Paradoxically, long-term (12 h) NOS inhibition caused an increase in PCD to compensate for the high proliferation rate under these conditions. Long-term treatment with a NO donor caused a decrease in S phase and increased PCD. The effects produced by the NO donor could be alleviated by folic acid that facilitated entry into S phase and prevented PCD. The effects produced by NOS inhibition (12 h) could be overcome by an embryo extract, used as a source of extracellular survival factors that enhanced proliferation and prevented PCD. Taken together, these data demonstrate that changing endogenous NO levels affect the balance between cell proliferation and PCD in NT of the developing chick embryo.


Asunto(s)
Apoptosis/fisiología , Ciclo Celular/fisiología , Sistema Nervioso Central/embriología , Óxido Nítrico/metabolismo , Animales , Sistema Nervioso Central/citología , Sistema Nervioso Central/efectos de los fármacos , Embrión de Pollo , Inhibidores Enzimáticos/farmacología , Ácido Fólico/farmacología , Donantes de Óxido Nítrico/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/metabolismo , S-Nitroso-N-Acetilpenicilamina/farmacología , omega-N-Metilarginina/farmacología
14.
Dev Dyn ; 225(3): 271-6, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12412009

RESUMEN

In all developing epithelia, the nuclei continually migrate between the apical and basal sides of the cell during the cell cycle, with S phase occurring basally and mitosis occurring apically. The purpose and mechanism of this nuclear migration are unknown. Here, we show that nitric oxide (NO) is endogenously produced in the developing chicken neural tube, where it apparently regulates cell-cycle progression. We provide evidence that high NO levels promote entry into S phase basally, whereas low levels of NO facilitate entry into mitosis apically.


Asunto(s)
Sistema Nervioso Central/embriología , Óxido Nítrico/metabolismo , Fase S/fisiología , Animales , División Celular/fisiología , Sistema Nervioso Central/citología , Embrión de Pollo , Células Epiteliales/citología , Células Epiteliales/enzimología , Mitosis/fisiología , Óxido Nítrico Sintasa/metabolismo , Somitos/citología , Somitos/enzimología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...